查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018811

血液分離設備市場：按產品類型、技術、患者類型、應用和最終用戶分類－2026-2032年全球市場預測

Apheresis Equipment Market by Product Type, Technology, Patient Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年血液分離設備市場價值為 34.5 億美元，預計到 2026 年將成長至 37.8 億美元，複合年成長率為 9.33%，到 2032 年將達到 64.5 億美元。

主要市場統計數據
基準年 2025 34.5億美元
預計年份：2026年 37.8億美元
預測年份 2032 64.5億美元
複合年成長率 (%) 9.33%

血漿分離設備的現況：影響採購和臨床實施的臨床因素、技術選擇和實際操作情況

血液分離設備處於臨床照護、細胞治療創新和捐贈者管理的關鍵節點，影響血液成分和治療性細胞的採集、處理和輸送方式。系統自動化、耗材設計和病原體控制的最新進展正在拓展設備的功能範圍，使CAR-T細胞療法和幹細胞療法的細胞採集流程更加精準，同時支持可擴展的血漿捐獻和治療性血液分離術。同時，從專科醫院和血站到研究機構和社區診所，設備安裝環境的多樣化也推動了對更多種類設備和服務模式的需求，而易用性、安全性和與臨床檢查室的下游整合性也日益受到重視。

自動化、病原體控制和分散式照護模式的快速發展正在重新定義醫療設備設計、服務期望和臨床工作流程。

血液分離領域的變革並非僅源自於產品的漸進式升級，而是一系列顛覆性的變革正在重塑整個治療流程和經營模式。細胞治療計畫的激增提升了專用細胞採集流程的重要性，推動了分離系統和耗材的創新，從而確保CAR-T細胞和幹細胞應用中細胞的高存活率和溫和處理。同時，病原體去活化技術的進步正在重新定義血漿採集和輸注流程的安全標準，進一步增強了醫療設備功能與血站操作規程的兼容性。

本檢驗了基於關稅的進口壓力對整個生態系統的供應鏈、供應商選擇和採購計畫的營運和策略影響。

近期政策週期顯著改變了血液分離設備採購的政策環境，迫使各機構重新評估其供應商、庫存和製造地。進口零件和成品系統關稅帶來的成本壓力，促使供應商更加多元化，並採取近岸外包策略。採購團隊需要在單價、準時交貨可靠性和供應商長期信譽之間權衡取捨。對許多相關人員，這導致他們在選擇供應商時採取更加謹慎的態度，嚴格審查零件來源、供應商財務狀況以及應對未來貿易中斷的合約保障措施。

詳細的細分分析揭示了產品類型、臨床應用、最終用戶畫像和技術選擇如何相互交織，從而創造差異化和價值。

要整體情況了解血液分離設備，需要從產品類型、應用、最終用戶、技術和患者族群等方面進行深入觀點。這些因素都會影響採購邏輯和臨床部署。血液分離試劑盒及配件、細胞分離系統、病原體去活化系統和血漿分離系統等產品之間的差異會影響採購週期和收入模式。一次性試劑盒等耗材通常是持續收入來源的基礎，需要完善的物流系統；而資本密集型分離設備則需要長期投入服務和培訓。應用層面的細分更凸顯了這個趨勢。細胞採集活動，包括CAR-T細胞採集和幹細胞採集，需要針對細胞活力、處理速度和封閉式工作流程進行最佳化的系統。另一方面，從單一血漿到來源血漿的血漿捐贈流程則優先考慮處理能力、捐贈者舒適度和病原體減少能力。研究應用和治療性血液分離術各有特定的文件要求和效能預期，這些都會影響設備配置和售後支援。

世界各地市場在基礎設施、法規和臨床重點領域的區域差異決定了其採用曲線、採購行為和夥伴關係需求。

區域趨勢顯著影響血液分離設備的普及、支持和規模化應用，其差異根源於醫療基礎設施、管理體制、捐血模式和臨床重點領域。在美洲，強大的臨床網路、大量的細胞治療臨床試驗以及完善的血液中心基礎設施，自然地催生了對先進細胞分離系統和整合耗材供應鏈的需求。該地區的採購流程往往側重於供應商的服務能力、臨床培訓項目以及在高容量中心久經考驗的運作可靠性。相較之下，歐洲、中東和非洲（EMEA）地區的情況則更為複雜，監管協調、國家血液服務模式以及醫療成本的波動都會影響其普及模式。儘管集中式醫療體系和國家採購機制傾向於標準化平台和長期服務契約，但該地區的新興市場則需要成本最佳化的解決方案和靈活的普及模式。

技術差異化、消費生態系統和卓越服務如何決定設備供應商之間的競爭優勢和夥伴關係重點。

醫療設備製造商、耗材供應商和服務供應商之間的競爭格局取決於技術差異化、售後市場收入以及臨床支援能力的綜合表現。市場領導者往往會大力投資其耗材生態系統（例如一次性耗材包和配件），以確保持續的需求並提高終端用戶的轉換成本。同時，隨著醫院和血站尋求能夠減少操作人員差異並簡化培訓的供應商，透過軟體工具、自動化等級和整合臨床支援服務實現差異化正成為採購談判中的決定性因素。

製造商和供應商的具體策略重點是加強供應鏈韌性、加速臨床部署並確保永續的收入來源。

產業領導企業應採取多管齊下的策略，在短期業務永續營運和長期創新之間取得平衡，以掌握臨床和商業機會。首先，他們應優先考慮供應鏈的透明度和冗餘性，具體措施包括：對關鍵耗材的多個供應商進行認證；最佳化一次性試劑盒的庫存策略；評估區域製造和委託製造方案，以減少進口相關的中斷。其次，他們應投資於自動化和軟體功能，以減少操作人員的差異並縮短訓練週期，從而提高細胞採集和血漿捐贈流程的處理能力和臨床一致性。第三，他們應開發模組化產品架構，允許在不更換整個系統的情況下升級病原體去活化模組和增強型資料介面等功能，從而提高產品生命週期價值並簡化採購決策。

臨床訪談、技術文件、監管記錄和採購分析均經過嚴格的交叉核對，以確保基於證據的見解和操作有效性。

本執行摘要的分析結合了第一手和第二手研究，並針對血液分離設備的技術和操作特性進行了客製化。第一手研究包括對醫院、血站、診所和研究機構的臨床使用者進行結構化訪談，以及與設備工程師、供應鏈經理和監管專家進行討論，以了解操作挑戰和供應商績效的考量。第二手研究涵蓋了設備手冊、監管申報文件、臨床試驗註冊數據、同行評審文獻和技術白皮書，檢驗性能聲明、追蹤技術進步並評估與臨床方案的兼容性。

整合臨床、技術和營運要求，以確定血液分離設備永續部署和商業性成功的路徑。

這些研究結果綜合起來表明，血漿分離術生態系統正在經歷變革時期。技術進步和臨床需求正在推動新的系統功能和服務模式的出現，而政策和供應鏈壓力則正在重塑採購和生產方式。自動化、改進的病原體管理以及客製化耗材設計的整合，使得更安全、更有效率的工作流程得以實現，從而支持高通量血漿採集和用於細胞治療的精細細胞採集。同時，受關稅影響的進口趨勢和區域監管差異凸顯了製定前瞻性供應鏈策略和增強本地化回應能力的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血液分離設備市場：依產品類型分類

  • 血液分離套裝及配件
  • 細胞分離系統
  • 病原體去活化系統
  • 電漿分離系統

第9章 血液分離設備市場：依技術分類

  • 離心分離技術
    • 全自動系統
    • 半自動系統
  • 膜技術
    • 批次處理系統
    • 連續流系統

第10章：依病患類型分類的血液分離設備市場

  • 成人版
  • 兒童

第11章 血液分離設備市場：依應用領域分類

  • 細胞收集
    • CAR-T細胞採集
    • 幹細胞採集
  • 血漿捐獻
    • 單一供體血漿
    • 原始血漿
  • 出於研究目的
  • 治療性血液分離術

第12章 血液分離設備市場：依最終用戶分類

  • 血液中心
  • 診所
  • 醫院
    • 綜合醫院
    • 專科醫院
  • 研究機構
    • 學術機構
    • 私營機構

第13章 血液分離設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血液分離設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血液分離設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血液分離設備市場

第17章：中國血液分離設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aikang Diagnostics Co., Ltd.
  • Asahi Kasei Kuraray Medical CoLtd.
  • BBraun Melsungen AG
  • Bioelettronica Srl
  • Cerus Corporation
  • Charles River Laboratories International, Inc.
  • Cytosorbents Corporation
  • Delcon Srl
  • Ekso Bionics Holdings Inc.
  • Fenwal by Carrier Global Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Isto Biologics
  • JMS North America Corporation
  • Kaneka Corporation
  • LMB Technologie GmbH
  • Maco Pharma SAS
  • Mallinckrodt Pharmaceuticals Ireland Limited
  • MEDICA SPA
  • Medicap Clinic GmbH
  • Miltenyi Biotec BV & Co. KG
  • Nikkiso Europe GmbH
  • SB-Kawasumi Laboratories, Inc.
  • Terumo BCT Inc
Product Code: MRR-ED54C46E8736

The Apheresis Equipment Market was valued at USD 3.45 billion in 2025 and is projected to grow to USD 3.78 billion in 2026, with a CAGR of 9.33%, reaching USD 6.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.45 billion
Estimated Year [2026] USD 3.78 billion
Forecast Year [2032] USD 6.45 billion
CAGR (%) 9.33%

Setting the scene for apheresis equipment: clinical drivers, technology choices, and operational realities shaping procurement and clinical adoption

Apheresis equipment sits at the intersection of clinical care, cellular therapy innovation, and donor management, shaping how blood components and therapeutic cells are collected, processed, and delivered. Recent advances in system automation, consumable design, and pathogen mitigation have expanded the functional scope of devices, enabling more precise cell collection workflows for CAR T and stem cell therapies, while supporting scalable plasma donation and therapeutic apheresis procedures. Concurrently, the diversification of settings-from specialized hospitals and blood centers to research institutes and community clinics-has driven demand for a wider array of device form factors and service models, with a growing emphasis on usability, safety, and downstream integration with clinical laboratories.

In practical terms, stakeholders must balance capital procurement with recurring consumable needs, integrate technology choices that align with clinical protocols and patient types, and maintain supply chain continuity for critical kits and accessories. Technology choices such as centrifugal and membrane platforms continue to influence workflow design, with implications for automation level, throughput, and clinical staff training. End users including general and specialty hospitals, blood centers, and both academic and commercial research institutes prioritize reliability, vendor support, and clinical evidence when selecting equipment. Meanwhile, regulatory scrutiny and donor safety requirements shape device acceptance and clinical uptake across geographies. Taken together, these forces make the apheresis equipment environment both technically complex and strategically consequential for providers, manufacturers, and research organizations.

How rapid advances in automation, pathogen control, and decentralized care models are redefining device design, service expectations, and clinical workflows

The apheresis landscape is being reshaped by a set of transformative shifts that extend beyond incremental product upgrades to alter entire care pathways and business models. The surge in cell therapy programs has elevated the importance of dedicated cell collection workflows, prompting innovation in separator systems and consumables that support high-viability yields and gentle handling for CAR T and stem cell applications. At the same time, improvements in pathogen inactivation technologies are redefining safety expectations for plasma collection and transfusion workflows, prompting greater alignment between device capabilities and blood center protocols.

Automation and software-driven process control are enabling previously manual steps to be standardized, which reduces operator variability and shortens training timelines. As a consequence, full and semi-automation options within centrifugal and membrane technology families are attracting different types of buyers based on throughput needs and clinical complexity. Additionally, a move toward decentralized models of care and point-of-donor testing is nudging suppliers to design more compact, interoperable systems that can be deployed in clinic-level settings. Regulatory frameworks and reimbursement pathways are also evolving in tandem, creating new pathways for clinical adoption while imposing higher expectations for clinical evidence and post-market surveillance. Finally, supply chain resiliency and environmental sustainability have emerged as strategic priorities, influencing material selection for kits and accessories and prompting manufacturers to rethink logistics and vendor relationships. Together, these shifts are accelerating the transition from isolated product sales to integrated service and solution offerings that combine devices, consumables, and data-driven support.

Examining the operational and strategic consequences of tariff-driven import pressures on supply chains, sourcing choices, and procurement timelines across the ecosystem

The policy environment influencing apheresis equipment procurement has changed materially due to tariff measures enacted in recent policy cycles, prompting organizations to reassess sourcing, inventory, and manufacturing footprints. Tariff-driven cost pressures on imported components and finished systems have increased emphasis on supplier diversification and nearshoring strategies, with procurement teams evaluating trade-offs between unit price, delivery certainty, and long-term vendor reliability. For many stakeholders, this has translated into a more deliberate approach to supplier qualification, with greater scrutiny of component origin, supplier financial resilience, and contractual protections against future trade disruption.

Clinicians and hospital procurement functions have responded by extending inventory lead times for critical consumables, especially single-use kits and accessories that are susceptible to supply chain variability. At the same time, manufacturers have accelerated efforts to secure alternative supply sources, invest in localized manufacturing capacity where feasible, and redesign packaging and logistics to mitigate tariff impacts. These adaptations have also affected how research institutes and commercial entities plan clinical programs: extended lead times for specialized cell separator systems or pathogen inactivation consumables necessitate earlier procurement planning and contingency reserves.

Regulatory and compliance teams have had to reconcile the operational need to diversify sources with local registration requirements and quality assurance standards, ensuring that alternate suppliers meet the same clinical and safety benchmarks. In aggregate, tariff pressures have nudged the ecosystem toward greater supply-chain transparency, increased inventories for critical SKUs, and closer collaboration between device manufacturers, component suppliers, and end users to preserve continuity of care and clinical research timelines.

Detailed segmentation analysis revealing how product categories, clinical applications, end user profiles, and technology choices intersect to drive differentiation and value

Understanding the apheresis equipment landscape requires a granular view across product types, applications, end users, technologies, and patient populations, each of which shapes purchasing logic and clinical deployment. Product distinctions between apheresis kits and accessories, cell separator systems, pathogen inactivation systems, and plasma separation systems drive different procurement cycles and revenue models; consumables such as single-use kits often underpin recurring revenue streams and demand well-established logistics, whereas capital-intensive separators require long-term service and training investments. Application-level segmentation further refines this dynamic: cell collection activities, encompassing both CAR T cell collection and stem cell collection, demand systems optimized for cell viability, processing speed, and closed-system workflows, while plasma donation pathways-ranging from single donor plasma to source plasma-prioritize throughput, donor comfort, and pathogen reduction capabilities. Research use and therapeutic apheresis each impose specific documentation and performance expectations that influence device configuration and aftermarket support.

End users present another axis of differentiation. Blood centers operate at scale with repeatable donor flows and stringent regulatory reporting, clinics often seek compact, user-friendly platforms to support lower-volume programs, and hospitals-whether general or specialty-balance a mix of acute care needs with procedural throughput considerations. Research institutes, divided into academic and commercial entities, demand specialized interfaces for experimental protocols and close collaboration with manufacturers on validation and customization. On the technology front, centrifugal and membrane approaches offer distinct trade-offs: centrifugal platforms, available in full automation and semi-automation variants, generally emphasize closed-system handling and established clinical ergonomics, while membrane-based systems, including batch and continuous flow formats, can offer modularity and different performance envelopes for specific applications. Finally, patient type segmentation between adult and pediatric populations affects device settings, consumable sizing, and clinical training priorities, requiring manufacturers and providers to tailor protocols and support materials accordingly. Synthesizing these segmentation layers enables targeted product development and commercially viable service strategies that match clinical realities.

Regional nuances in infrastructure, regulation, and clinical focus that determine adoption curves, procurement behavior, and partnership needs across global markets

Regional dynamics significantly shape how apheresis equipment is adopted, supported, and scaled, with differences rooted in healthcare infrastructure, regulatory regimes, donation models, and clinical focus areas. In the Americas, robust clinical networks, a high prevalence of cell therapy trials, and established blood center infrastructures create natural demand for advanced cell separator systems and integrated consumable supply chains. Procurement processes in this region tend to emphasize vendor service capabilities, clinical training programs, and evidence of operational reliability across high-throughput centers. Conversely, Europe, the Middle East & Africa features a more heterogeneous landscape where regulatory harmonization, national blood service models, and variable healthcare spending influence adoption patterns; centralized health systems and national procurement mechanisms often favor standardized platforms and long-term service arrangements, while emerging markets within the region require cost-optimized solutions and flexible deployment models.

Asia-Pacific presents a diverse mix of opportunities and constraints: major metropolitan centers and research hubs are rapidly building capacity for cell therapy programs and high-volume plasma collection, driving demand for both automated separators and pathogen inactivation technologies. At the same time, differences in regulatory timelines, local manufacturing incentives, and reimbursement frameworks create a patchwork of adoption speeds across countries. Across all regions, localization of supply chains, clinical training, and aftermarket service capabilities remain critical for sustained adoption. Regional stakeholders increasingly prioritize partnerships that deliver not just equipment but a comprehensive package of training, consumable supply assurance, and data-driven support to optimize clinical throughput and donor safety.

How technology differentiation, consumable ecosystems, and service excellence determine competitive advantage and partnership priorities among equipment suppliers

Competitive dynamics among device manufacturers, consumable suppliers, and service providers are defined by a combination of technological differentiation, aftermarket revenue focus, and clinical support capabilities. Market leaders tend to invest heavily in consumables ecosystems-single-use kits and accessories-that lock in recurring demand and create high switching costs for end users. At the same time, differentiation through software tools, automation levels, and integrated clinical support services is becoming a decisive factor in procurement discussions, as hospitals and blood centers seek vendors that can reduce operator variability and streamline training.

Collaboration between manufacturers and research institutes is accelerating innovation cycles, especially for cell collection systems tailored to CAR T and stem cell protocols. Strategic partnerships, co-development agreements, and clinical trial support arrangements help bridge the gap between laboratory methods and scalable clinical workflows. Additionally, companies that offer robust global service networks, including local parts availability and responsive technical support, gain competitive advantage in markets where uptime is directly linked to clinical throughput and donor retention. Longer-term strategies increasingly include investments in localized manufacturing, modular product architectures that permit incremental upgrades, and sustainability initiatives to reduce the environmental footprint of consumables and packaging. Collectively, these approaches shape a competitive environment where technical performance, service quality, and supply security matter as much as device specifications.

Actionable strategic priorities for manufacturers and providers to strengthen supply resilience, accelerate clinical adoption, and capture recurring revenue streams

Industry leaders should adopt a multifaceted strategy that balances near-term operational resilience with long-term innovation to capture clinical and commercial opportunities. First, prioritize supply chain transparency and redundancy for critical consumables by qualifying multiple suppliers, optimizing inventory policies for single-use kits, and evaluating regional manufacturing or tolling options to mitigate import-related disruptions. Second, invest in automation and software capabilities that reduce operator variability and shorten training cycles, thereby improving throughput and clinical consistency for both cell collection and plasma donation workflows. Third, develop modular product architectures that allow customers to upgrade functionality-such as pathogen inactivation modules or enhanced data interfaces-without full system replacement, increasing lifetime value and easing procurement decisions.

Additionally, strengthen clinical partnerships by supporting investigator-initiated trials and co-development programs with academic and commercial research institutes; these collaborations accelerate validation of novel protocols and create a pipeline of evidence that underpins adoption. For commercial strategy, align pricing models with end-user economics by offering bundled options that combine capital equipment, consumable subscriptions, and performance-based service commitments. From a regulatory perspective, harmonize submissions across key jurisdictions and prepare robust post-market surveillance strategies to meet evolving safety expectations. Finally, embed sustainability and circular-economy considerations into product design and logistics planning to address growing environmental and procurement requirements, while communicating these efforts clearly to customers as a differentiator in institutional purchasing decisions.

A rigorous triangulation of clinical interviews, technical documentation, regulatory records, and procurement analysis to ensure evidence-based insights and operational relevance

The analysis underpinning this executive summary combined primary and secondary evidence tailored to the technical and operational characteristics of apheresis equipment. Primary research included structured interviews with clinical users across hospitals, blood centers, clinics, and research institutes, as well as discussions with device engineers, supply chain managers, and regulatory specialists to capture real-world deployment challenges and vendor performance considerations. Secondary research encompassed device manuals, regulatory filings, clinical trial registries, peer-reviewed literature, and technical white papers to validate performance claims, trace technology evolution, and assess compatibility with clinical protocols.

Supplementary inputs included analyses of procurement patterns and service models, review of patent landscapes to identify innovation trends, and examination of policy and trade developments affecting component sourcing and logistics. Where applicable, technical specifications were compared across centrifugal and membrane platforms to understand automation capabilities and consumable footprints. All findings were triangulated through cross-validation from multiple sources to ensure reliability and relevance for decision-makers. Throughout the research process, emphasis was placed on clinical applicability and operational feasibility rather than speculative projections, resulting in insights designed to inform procurement, R&D prioritization, and strategic partnerships.

Synthesis of clinical, technological, and operational imperatives that define the path to durable adoption and commercial success in apheresis equipment

The collective insights reveal an apheresis ecosystem in transition: technological advances and clinical demand are spurring new system capabilities and service models, while policy and supply chain pressures are reshaping procurement and manufacturing choices. The convergence of automation, improved pathogen control, and tailored consumable design is enabling safer, more efficient workflows that support both high-throughput plasma collection and delicate cell therapy harvests. At the same time, tariff-driven import dynamics and regional regulatory variability underscore the need for proactive supply chain strategies and localized support capabilities.

For stakeholders across the value chain, the imperative is clear: align product development with clinical workflows, secure recurring consumable revenue through reliable logistics and training, and invest in partnerships that accelerate clinical validation. By combining technical performance with robust service offerings and supply continuity, manufacturers and providers can deliver solutions that meet both immediate operational needs and long-term clinical goals. The path forward favors organizations that think holistically about devices as part of an ecosystem encompassing consumables, software, clinical evidence, and service.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Apheresis Equipment Market, by Product Type

  • 8.1. Apheresis Kits & Accessories
  • 8.2. Cell Separator Systems
  • 8.3. Pathogen Inactivation Systems
  • 8.4. Plasma Separation Systems

9. Apheresis Equipment Market, by Technology

  • 9.1. Centrifugal Technology
    • 9.1.1. Full Automation Systems
    • 9.1.2. Semi Automation Systems
  • 9.2. Membrane Technology
    • 9.2.1. Batch Systems
    • 9.2.2. Continuous Flow Systems

10. Apheresis Equipment Market, by Patient Type

  • 10.1. Adult
  • 10.2. Pediatric

11. Apheresis Equipment Market, by Application

  • 11.1. Cell Collection
    • 11.1.1. Car T Cell Collection
    • 11.1.2. Stem Cell Collection
  • 11.2. Plasma Donation
    • 11.2.1. Single Donor Plasma
    • 11.2.2. Source Plasma
  • 11.3. Research Use
  • 11.4. Therapeutic Apheresis

12. Apheresis Equipment Market, by End User

  • 12.1. Blood Centers
  • 12.2. Clinics
  • 12.3. Hospitals
    • 12.3.1. General Hospitals
    • 12.3.2. Specialty Hospitals
  • 12.4. Research Institutes
    • 12.4.1. Academic Institutes
    • 12.4.2. Commercial Institutes

13. Apheresis Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Apheresis Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Apheresis Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Apheresis Equipment Market

17. China Apheresis Equipment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aikang Diagnostics Co., Ltd.
  • 18.6. Asahi Kasei Kuraray Medical CoLtd.
  • 18.7. BBraun Melsungen AG
  • 18.8. Bioelettronica S.r.l.
  • 18.9. Cerus Corporation
  • 18.10. Charles River Laboratories International, Inc.
  • 18.11. Cytosorbents Corporation
  • 18.12. Delcon S.r.l.
  • 18.13. Ekso Bionics Holdings Inc.
  • 18.14. Fenwal by Carrier Global Corporation
  • 18.15. Fresenius Kabi AG
  • 18.16. Haemonetics Corporation
  • 18.17. Isto Biologics
  • 18.18. JMS North America Corporation
  • 18.19. Kaneka Corporation
  • 18.20. LMB Technologie GmbH
  • 18.21. Maco Pharma SAS
  • 18.22. Mallinckrodt Pharmaceuticals Ireland Limited
  • 18.23. MEDICA S.P.A.
  • 18.24. Medicap Clinic GmbH
  • 18.25. Miltenyi Biotec B.V. & Co. KG
  • 18.26. Nikkiso Europe GmbH
  • 18.27. SB-Kawasumi Laboratories, Inc.
  • 18.28. Terumo BCT Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL APHERESIS EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL APHERESIS EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY APHERESIS KITS & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY APHERESIS KITS & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY APHERESIS KITS & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL SEPARATOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL SEPARATOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL SEPARATOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PATHOGEN INACTIVATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PATHOGEN INACTIVATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PATHOGEN INACTIVATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY FULL AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY FULL AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY FULL AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SEMI AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SEMI AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SEMI AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BATCH SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BATCH SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BATCH SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CAR T CELL COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CAR T CELL COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CAR T CELL COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY STEM CELL COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY STEM CELL COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY STEM CELL COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SINGLE DONOR PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SINGLE DONOR PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SINGLE DONOR PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SOURCE PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SOURCE PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SOURCE PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY THERAPEUTIC APHERESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY THERAPEUTIC APHERESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY THERAPEUTIC APHERESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BLOOD CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BLOOD CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY BLOOD CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY COMMERCIAL INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY COMMERCIAL INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY COMMERCIAL INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. G7 APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL APHERESIS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA APHERESIS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY MEMBRANE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY CELL COLLECTION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY PLASMA DONATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA APHERESIS EQUIPMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)